Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Novo Nordisk A/S has a fifty-two week low of $60.61 and a fifty-two week high of $148.15. The company has a market capitalization of $285.03 billion, a price-to-earnings ratio of 19.31, a P/E/G ...

PITTSBURGH (CN) — Bashing a Biden-era law that gives Medicare the power to directly negotiate the price of certain high-cost prescription drugs, an attorney for the pharmaceutical giant Novo Nordisk ...

Novo Nordisk is considering launching its weight loss injection Wegovy in India sooner than planned to better challenge U.S. rival Eli Lilly, Reuters reports, citing unnamed sources. --The Danish ...